ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

3:00PM-4:30PM: Abstract Number: 2606

Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis

Abstracts: Health Services Research II

3:00PM-4:30PM: Abstract Number: 2637

Chaperone-mediated Autophagy in Synovitis Distinguishes Psoriatic Arthritis from Rheumatoid Arthritis

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

3:00PM-4:30PM: Abstract Number: 2652

Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

3:00PM-4:30PM: Abstract Number: 2605

Clarifying Misbeliefs & Resolving Decisional Conflicts About Hydroxychloroquine (HCQ) Through a Shared Decision-Making Tool (HCQ-SAFE©)

Abstracts: Health Services Research II

3:00PM-4:30PM: Abstract Number: 2647

Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

3:00PM-4:30PM: Abstract Number: 2628

Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study

Abstracts: Pediatric Rheumatology – Clinical II

3:00PM-4:30PM: Abstract Number: 2607

Clinical Outcomes and Costs of Care for Patients Within the Rheumatoid Arthritis Care Pathway Cohort at a Tertiary Care Integrated Delivery Network: A Comparison to Usual Care

Abstracts: Health Services Research II

3:00PM-4:30PM: Abstract Number: 2596

Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF-κB/p65 in RA-FLS

Abstracts: Cytokines & Cell Trafficking

3:00PM-4:30PM: Abstract Number: 2640

Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

3:00PM-4:30PM: Abstract Number: 2611

Continuation versus Temporary Interruption of Immunomodulatory Agents in Case of an Infection in IRD Patients: Results of a Randomized Controlled Trial

Abstracts: Infection-related Rheumatic Disease

3:00PM-4:30PM: Abstract Number: 2629

Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity

Abstracts: Sjögren's Syndrome – Basic & Clinical Science

3:00PM-4:30PM: Abstract Number: 2649

Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

3:00PM-4:30PM: Abstract Number: 2638

Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

3:00PM-4:30PM: Abstract Number: 2627

Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis

Abstracts: Pediatric Rheumatology – Clinical II

3:00PM-4:30PM: Abstract Number: 2648

Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].